

Allomatrix

Bone Graft in a Distal Radial Fracture Model

A Prospective Randomized Controlled Clinical Trial



UNIVERSITÉ CATHOLIQUE DE LOUVAIN (UCL)

Cliniques Universitaires Saint-Luc

SERVICE DE CHIRURGIE ORTHOPÉDIQUE
ET DE TRAUMATOLOGIE

Dr Priscilla D'AGOSTINO

CONTENTS

- Introduction
- Material & Methods
- Results
- Discussion
- Conclusions




- Disclosure

NO FINANCIAL INTERESTS...

● DBM definition

Acid extraction from human cortical bone



● Interest of DBM grafts in Humans?

Literature > No Proven

● Study Objectives

Primary

➡ AlloMatrix and bone-healing ?

Secondary

➡ AlloMatrix and functional recovery?

● Study Design

- One Center
- Ethical Committee Approval (UCL)
- Registered by US NIH
- Prospective Randomized Controlled
- Between 2005 and 2008
- 50 patients
- DRF
- One Surgeon (+Assistants)
- AlloMatrix injectable DBM
- Randomization Envelopes
- Two R/ groups : Static K-wires stabilization +/- DBM graft
- No Blinding

● Fracture Model

Unstable DRF with dorsal bending of metaphysis +/- ulnar styloid



Orthopaedic Surgery most common fracture *Court-Brown and Caesar, Injury 2006*



● Study Population

Young patients

← Quality of anatomic result ↔ Wrist residual capacity

Villar and March, JBJS 1987

McQueen and Caspers, JBJS 1988

Young and Rayan, JBJS 2000

Kopylov et al., J Hand Surg 2002

Hollevoet and Verdonk, Acta Orthopaedica Belgica 2003

● Inclusion Criteria

- ❖ Unstable DRF
Lafontaine et al., Injury 1989
- ❖ High demand patient
- ❖ 18-70 years of age
- ❖ Follow-up possible
- ❖ Informed consent

Exclusion Criteria

- ❖ Complex DRF
- ❖ Bilateral DRF
- ❖ Other skeletal injury
- ❖ Pregnancy
- ❖ Preexisting conditions

● Patient Evaluation Schedule and Sequence

	IC	Fonctional evaluation	DASH questionnaire	Standard X-rays	BMDs
Pre-Op	●			●	
Surgery				●	
1 W F-U		●	●	●	●
3 W F-U		●	●	●	
6 W F-U		●	●	●	●
9 W F-U		●	●	●	
6 M F-U		●	●	●	
12 M F-U		●	●	●	●

● Implant Data

AlloMatrix™ = Injectable DBM Allograft + Calcium Sulfate carrier (Wright USA)

- *kit with different components*
- *5cc volume / syringe*



In vitro bio-assay test for osteoinductivity *Adkisson et al., J Orthop Res 2000*

Indication : fill bony voids (surgical or traumatic)

● Surgical Protocol

Operated within a week / Previous manual closed reduction or Japanese fingers traps + cast

External closed reduction and criteria
Friberg and Lundström, Acta Radiol Diagn 1976



Static 2 or 3 K-wires stabilization

➡ 2 transtyloid K-wires +/- 1 dorso-ulnar K-wire




Fernandez and Jupiter 1996
Fernandez and Wolfe 2005

● Surgical Protocol

Randomization envelope

+/- Grafting by limited dorsal approach



Open cast → Removable thermoplastic / Early active digital and forearm motion

Removal K-wires between 6-8 W

Hand therapist active and passive wrist motion

• Clinical Evaluation Protocol

Objective Functional Analysis : - Range of motion *Solgaard et al., Scand J Rehab Med 1986*
- Strength *Mathiowetz, Muscle Strength Testing 1990*

Subjective Functional Analysis : - DASH questionnaire *Hudak et al., Am J Ind Med 1996*




Standardized and Reproducible Methods (ASHT)

● Radiographic Analysis Protocol

PA and lateral views :

- Morphology assessment *Medoff, Hand Clin 2005*





- Union criteria
Morshed et al., JBJS 2008; Corrales et al., JBJS 2008
- Extraskeletal AlloMatrix deposits occurrence



Kodak® Carestream PACS software (Eastman Kodak Company, 2005)

● Bone Density Evaluation Protocol

Hip and lumbar spine at **1w**




Both wrists at **1-6w** and **1Y**



HOLOGIC® Dual Energy X-ray Absorptiometry Scan (DEXA scan)


● Preoperative data

Parameters	Graft Group
Gender (sex) †	M = 13 (26 %) F = 11 (22 %)
Age (years) *	42,25 (SD: 11,40) 20-62
Height (cm) *	171,6 (SD: 7,44) 158-182
Weight (Kg) *	70,8 (SD: 12,05) 49-98
BMI (Kg/m ²) *	24,02 (SD: 3,60) 18,67-35,16
Injured side †	R = 9 (37,5 %) L = 15 (62,5 %)
Dominance †	R = 19 L = 4 ? = 1
Fracture type †	E = 19 (38 %) I = 5 (10 %)
Ulnar fracture †	Ulnar Styl. = 13 (26 %) Ulnar Head = 2 (4 %)




● Preoperative data

Parameters	No Graft Group
Gender (sex) †	M = 8 (16 %) F = 18 (36 %)
Age (years) *	45 (SD: 14,39) 17-69
Height (cm) *	168,6 (SD: 11,35) 151-200
Weight (Kg) *	67,3 (SD: 14,25) 47-90
BMI (Kg/m ²) *	23,58 (SD: 3,96) 17,53-31,63
Injured side †	R = 14 (53,8 %) L = 12 (46,2 %)
Dominance †	R = 22 L = 1 ? = 3
Fracture type †	E = 21 (42 %) I = 5 (10 %) Ulnar Styl. = 15 (30 %)
Ulnar fracture †	Ulnar Head = 0 (0 %)




● Preoperative data

Parameters	P Value
Gender (sex) †	0.15
Age (years) *	0.46
Height (cm) *	0.28
Weight (Kg) *	0.19
BMI (Kg/m ²) *	0.62
Injured side †	0.27
Dominance †	0.35
Fracture type †	1.00
Ulnar fracture †	0.68




● Surgery data

- Interval injury-operation = 1,9 days **G** / 2 days **NG**
- 52% static 2 K-wires / 44% 3 K-wires / 4% others
- 24 **G** / 26 **NG** patients
- Mean volume AlloMatrix
= 2,3cc (1-4cc)
- Mean time tourniquet inflation
= 31,2 min (0-65min)
- Mean surgery duration
= 45min **G** / 30min **NG**
Significantly higher in G (p=0,004)
- Mean time removal K-wires
= 8,3W (4-17W)



● Patient Flow


Clinical and Radiological Follow-up



Data analysis on an intention-to-treat basis

● Patient Flow

BMDs Follow-up



Mean post-op Follow-up = 15 months **G** / 14,2 months **NG**

No statistical significant difference between both groups ($p=0,9$)

● Preoperative Radiological Results

PA projection parameters	Graft group *	No Graft group *	P Value **
RI (°)	13 (SD: 5,94)	15,4 (SD: 6,32)	0,19
UV (mm)	0,8 (SD: 1,97)	1,1 (SD: 1,82)	0,63
RH (mm)	7,5 (SD: 3,60)	6,4 (SD: 3,30)	0,27

Standard lateral projection parameters	Graft group *	No Graft group *	P Value **
VT (°)	23,1 (SD: 6,67)	25 (SD: 10,24)	0,46
TD ↳ (°)	41,8 (SD: 11,7)	39,1 (SD: 12,56)	0,46

No statistical significant difference in preoperative fractures unstability

● Clinical Results : Objective and Subjective Outcomes

Did AlloMatrix improve and allow a faster functional recovery ?

No statistical significant differences between both groups

Statistical significant difference (strength) between noninjured and injured side

- pinch strength ($p=0,01$) at 6W (**G**)
- grip strength ($p=0,04$) at 9W (**G**)

● Postoperative Radiological Results

Did AlloMatrix increase postoperative fracture stability ?


No statistical significant difference between both groups

● Union Rate

Did AlloMatrix enhance bridging of the skeletal gap, bone union ?

No statistical significant difference in union rate and speed of union

Complete bridging of the fracture gap at 9W



● BMDs Results

Did AlloMatrix enhance bone density ?

No statistical significant difference on the injured side between both groups

Statistical significant difference in bone density higher in R1 zone ($p=0,05$) on the injured side in the Graft group at 1W



- Improvement between one week and one year within groups

Clinical and Radiological Outcomes

Range of Motion
Strength
Fracture-healing
Bone density

Significant
improvement
($p<0,001$ for all)

DASH scores



- Improvement between one week and one year within groups

Radiographic Parameters Outcomes

RI ($p=0,4$)

RH ($p=0,6$)


VT ($p=0,2$)

No significant
changes

UV ($p<0,001$)

TD* ($p=0,04$)

Significant changes
→ Progressive radial crush
in both groups



● Complications

Did AlloMatrix enhance morbidity ?

Peroperative	Graft group	No Graft group
Radial artery lesion	0	2
Postoperative	Graft group	No Graft group
Infection *	1	2
Flow of graft	1	0
CRPS I	3	1
Neurosensitive complaints	4	6
Tenderness on K-wires	3	1
Tendons rupture *	0	2
Trigger fingers	0	1
Dupuytren's disease	0	1
Wrist synovial cyst	1	0
Symptomatic malunion *	1	1

No increase in morbidity and surgical revisions in the Graft group



● Complications

Did AlloMatrix enhance morbidity ?


Peroperative	Graft group	No Graft group
Radial artery lesion	0	2
Postoperative	Graft group	No Graft group
Infection *	1	2
Flow of graft	1	0
CRPS I	3	1
Neurosensitive complaints	4	6
Tenderness on K-wires	3	1
Tendons rupture **	0	2
Trigger fingers	0	1
Dupuytren's disease	0	1
Wrist synovial cyst	1	0
Symptomatic malunion ***	1	1

No increase in morbidity and surgical revisions in the Graft group

- Extraskeletal AlloMatrix Deposits



● Extraskeletal AlloMatrix Deposits



Disappearance of all soft-tissue extrusions after 9W

● Safety and Morbidity

No adverse events observed

● Handling

Significant increase of surgical procedure time

Supplementary dorsal approach

➡ *Strength weakness / Dorsal wrist synovial cyst ?*


Difficulty for injection

➡ *Soft tissue deposits*

● Graft Resorption

No significant difference in R1 zone bone density at 6W
No extraskeletal deposits on X-rays after 9W

RESORPTION



● Variability in osteoinductivity

➡ Intervariability of BMPs in DBM grafts

Proportional osteoinduction related to [BMPs]

Han et al., J Orthop Res 2003

Yoo et al., Spine J 2003

Edwards, IsoTis OrthoBiologics 2003

Atti et al., Spine J 2003

Peterson et al., J Bone Joint Surg 2004

➡ AlloMatrix DBM content is **40%** by weight

DBM preparation and storage methods

Zhang et al., J Periodontol 1997

Han et al., J Orthop Res 2005

Ferreira et al., Clin Orthop Relat Res 2001

Alanay et al., Spine J 2008

Qiu et Connor, J Biomed Mater Res 2008

Pinholt and Solheim, Ann Plast Surg 1994

● Variability in osteoinductivity

➡ Intravariability of BMPs in a DBM graft

Highest variability in [BMPs] among lots of the same DBM formulation

Bae et al., Spine 2006

Human cadaver donors age

Young donors enhance osteoinductivity ?

Not supported in literature

Pinholt and Solheim, J Craniofac Surg 1998

Traianedes et al., J Biomed Mater Res B Appl Biomater 2004

- Variability in osteoinductivity

➡ PDGF in blood decrease DBM osteoinductivity

Ranly et al., J Bone Joint Surg 2005 and 2007

➡ Patient blood never adjunct or mix to AlloMatrix

- Sample size

Power of the analysis limitation

No significant clinical effect of AlloMatrix demonstrated in this human model

Additional trials needed | **to evaluate utility and potential benefits in humans**
to confirm our observations





Thank you for your attention

の種及術文写て 感ザ捺しオ会観美イ
英と字印 び技す 国出のシ品 致最ま
ゴ因ンは証 メ密万

刷の種 及術文写て 感ザ捺しオ会観美
D N E D A N A G E N T
T H E M A T R I X
I S
H E I S
T O P
C O M
E
B E L I E V E
T H E
U N B E L I E V A B L E
M A T R I X

